Oral Wegovy cleared
The FDA has approved an oral form of Wegovy after positive Phase III OASIS 4 results, positioning it as the pill version of a leading GLP‑1 obesity drug rather than an injection (Applied Clinical Trials). Novo Nordisk is planning a full U.S. launch and says manufacturing will be based in North Carolina, which could broaden access for patients who prefer pills over injections (Applied Clinical Trials).
Weight-loss drugs used to mean a weekly shot. In December 2025, the Food and Drug Administration cleared a once-daily Wegovy pill, making semaglutide the first oral glucagon-like peptide-1 medicine approved in the United States for obesity. (fda.gov) Semaglutide works by copying a gut hormone that tells the brain you have eaten and slows how fast food leaves the stomach. The older Wegovy version delivered that signal through an injection under the skin, while the new version delivers it as a tablet taken by mouth. (fda.gov) Getting this kind of drug into a pill has been hard because stomach acid and digestive enzymes chew up peptide medicines the way heat melts ice. Novo Nordisk solved that earlier in diabetes with oral semaglutide, and now it has pushed the same basic delivery idea into the obesity market under the Wegovy brand. (nejm.org) The approval rested on a Phase 3 study called OASIS 4 that followed 307 adults for 64 weeks. These were adults with obesity, or with overweight plus at least one weight-related medical problem, and they did not have diabetes. (appliedclinicaltrialsonline.com) In that trial, people taking the pill lost 13.6% of their body weight on average, versus 2.2% for placebo. Among participants who stayed on treatment as planned, average weight loss reached 16.6%. (appliedclinicaltrialsonline.com) The label says the pill is for adults with obesity, or adults with overweight plus at least one weight-related condition, alongside diet and physical activity. It is also approved to cut the risk of major cardiovascular events such as heart attack, stroke, or cardiovascular death in adults with known heart disease and obesity or overweight. (wegovy.com) The tradeoff is convenience versus routine. The injection is taken once a week, but the pill has to be taken every morning on an empty stomach with no more than 4 ounces of plain water, and patients must wait at least 30 minutes before eating, drinking, or taking other oral medicines. (wegovy.com) The safety warnings did not disappear when the needle did. The boxed warning still flags thyroid C-cell tumors seen in rodents, and common side effects still include nausea, diarrhea, vomiting, constipation, stomach pain, headache, and fatigue. (fda.gov) Novo Nordisk said in December 2025 that it was preparing a full United States launch in early January 2026, with manufacturing already underway in North Carolina. By April 2026, North Carolina biotechnology officials said the pill was available and being made at the company’s in-state facilities. (prnewswire.com) (ncbiotech.org) That does not mean injections are going away. It means the biggest obesity-drug market now has two delivery formats for the same medicine: a weekly pen for people who can live with a shot, and a daily pill for people who would rather build the drug into breakfast-time routine. (wegovy.com)
